Bimagrumab Plus Semaglutide: The Muscle Question

If the objection to GLP-1 drugs is that they take muscle along with fat, the obvious answer is a second drug that protects muscle. Bimagrumab is that drug, and a 2026 phase 2 trial tested it alone, with semaglutide, and against placebo in 507 adults. The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone.^[1] What the published summary does not report is the number the whole idea rests on.

What the trial found

Adults with obesity, or with overweight and at least one obesity-associated complication, were randomized across nine groups for 48 weeks, followed by an open-label extension to week 72. Bimagrumab is given intravenously every 12 weeks; it targets type II activin receptors, with the intent of reducing fat mass while promoting muscle growth.^[1]

Improvements continued through week 72. Bimagrumab’s common adverse events were muscle spasms, diarrhea and acne; semaglutide brought the familiar nausea, diarrhea, constipation and fatigue.^[1]

The number that is missing

Bimagrumab’s entire rationale is composition — not how much weight comes off, but what kind of tissue it is. The published summary reports total body weight and does not report the fat-versus-lean split.

A drug designed to change what you lose, reported by how much you lose. The headline figure is not the one the hypothesis is about.

So the honest reading is narrower than the excitement around this combination suggests. It establishes that adding bimagrumab produces more weight loss than semaglutide alone. It does not, in what has been published here, establish that the weight lost was more favorably composed — and that is the claim the drug exists to make. If you see this trial cited as proof that muscle was preserved, check whether the person citing it has a body-composition number or is assuming one.

What this is and is not, practically

• Phase 2, not phase 3. 507 people across nine arms means each arm is small, and phase 2 results routinely shrink when tested properly.
• An intravenous infusion every 12 weeks. This is not a pen you take home. It changes cost, access and who realistically receives it.
• Not available, and not close. Nobody can prescribe this combination outside a trial, and no compounder can lawfully supply it — see what cannot legally be compounded.
• New adverse events, not just more of the old ones. Muscle spasms and acne are bimagrumab’s, not semaglutide’s.

The direction is genuinely interesting: combination therapy aimed at composition rather than scale weight is where obesity medicine is going, and this is a real trial with a real result. It is also two years and a phase 3 program away from meaning anything to a reader.